KALA BIO, Inc. (KALA) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Apr 15, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for KALA BIO, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, KALA BIO, Inc.'s filing signal continuing negative.
earningsVibe SuperAnalyst™ Verdict: CONTINUING NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Turned Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Turned Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does KALA BIO, Inc. actually do?
Answer:
KALA BIO, Inc. is a biopharmaceutical company undergoing a strategic transition, shifting from developing eye-related therapies to establishing an AI infrastructure platform for the biotechnology industry. Following the failure of its lead product candidate, KPI-012, in a Phase 2b clinical trial in September 2025, the company decided to discontinue development of its MSC-S platform. KALA BIO is now focused on evaluating strategic alternatives for its legacy assets and developing a dedicated, on-premises AI platform called Researgency, licensed from Younet AI. This new venture aims to enable biotech and pharmaceutical companies to leverage their proprietary biological data securely within their own environments. The company's future success hinges on the adoption of this AI platform and the monetization of its remaining biologics assets.
Question:
What are KALA BIO, Inc.'s revenue drivers?
Answer:
The company has no current revenue-generating commercial products. Its future revenue will depend on the successful development and commercialization of its AI platform business, and potentially from monetization of its legacy biologics assets through licensing or strategic arrangements.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required